Aligos Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lawrence Blatt
- Full Time Employees
- 70
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Corporate Drive South San Francisco CA United States of America 94080
- IPO Date
- Oct 16, 2020
- CIK
- 0001799448
- Website
- aligos.com
- Similar Companies
- Business
- Aligos Therapeutics, Inc. (Nasdaq: ALGS) develops targeted antiviral and liver disease therapies addressing unmet needs in chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, COVID-19, and hepatitis delta virus (HDV). The company's lead product candidate, pevifoscorvir sodium (previously ALG-000184), is an oral small molecule capsid assembly modulator (CAM-E) in Phase 2 monotherapy for chronic HBV infection, demonstrating best-in-class reductions in viral markers including HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg in long-term Phase 1 studies with full 96-week data presented at AASLD The Liver Meeting 2025; ALG-055009, an oral thyroid hormone receptor beta (THR-β) agonist in Phase 2 for MASH and obesity, achieved statistically significant liver fat reductions in the Phase 2a HERALD study topline results in September 2024 with favorable tolerability including in GLP-1 combination; ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor in Phase 1/2 supported by over $13.8 million in NIAID/NIH funding, began three clinical trials in 2024 showing superior potency against SARS-CoV-2 variants; preclinical programs include proprietary antisense oligonucleotide (ASO) platforms for chronic HBV and HDV targeting viral genome destruction with improved toxicity profiles. In February 2025, Aligos completed a $105 million private placement financing to support pipeline advancement including the Phase 2 B-SUPREME study for pevifoscorvir sodium dosing initiated in August 2025 with interim data expected in 2026; Phase 1 studies for pevifoscorvir sodium in special populations and drug-drug interactions are ongoing under NIAID contract. Founded in 2018 and headquartered in South San Francisco, California, the company operates primarily in the United States with additional facilities in Heverlee, Belgium, and Shanghai, China, focusing on clinical-stage biopharmaceutical development for global markets in virology and hepatology.
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Consensus Rating of “Moderate Buy” from Analysts
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS)
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% – Time to Sell?
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Presents Positive Data at HEP-DART 2025